Evidence map›Paper›PMID 32653522›Full record

ReviewLife sciences2020

The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions.

Tapan Behl, Ishnoor Kaur, Simona Bungau, Arun Kumar, Md Sahab Uddin, Chanchal Kumar, Giridhari Pal, Sahil, Kamal Shrivastava, Gokhan Zengin and 1 more

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Life sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05630339 (Efficacy and Security of the Magnesium and Vitamin D Combination as Adjuvant Treatment of Post-COVID Syndrome. A Randomised Double-blind Clinical Trial), which is not on this map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
2.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05630339 nacompletednot on this mapstarted 2022, after this paper: background citation

Efficacy and Security of the Magnesium and Vitamin D Combination as Adjuvant Treatment of Post-COVID Syndrome. A Randomised Double-blind Clinical Trial

TypeinterventionalSponsorCoordinación de Investigación en Salud, MexicoRan2022 to 2023Enrolled150ConditionsPost-COVID-19 Syndrome, Long COVID, Vitamin D Deficiency, Magnesium DeficiencyArmsMagnesium chloride, Vitamin D, Inert placebo
3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 104 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Hyaluronan in the pathogenesis of acute and post-acute COVID-19 infection.Matrix biology : journal of the International Society for Matrix Biology · 2023
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Observational
  15. Article
  16. Passive Samplers, an Important Tool for Continuous Monitoring of the COVID-19 Pandemic.Environmental science and pollution research international · 2022
    Review
  17. Review
  18. Review
  19. ACE2 Receptor and Its Isoform Short-ACE2 Are Expressed on Human Spermatozoa.International journal of molecular sciences · 2022
    Article
  20. Anticipated pharmacological role of Aviptadil on COVID-19.Environmental science and pollution research international · 2022
    Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 4 countries.

Tapan BehlChitkara College of Pharmacy, Chitkara University, 140401, Punjab, India. Electronic address: tapanbehl31@gmail.com.
Ishnoor KaurChitkara College of Pharmacy, Chitkara University, 140401, Punjab, India.
Simona BungauDepartment of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Romania. Electronic address: sbungau@uoradea.ro.
Arun KumarChitkara College of Pharmacy, Chitkara University, 140401, Punjab, India.
Md Sahab UddinDepartment of Pharmacy, Southeast University, 1213 Dhaka, Bangladesh; Pharmakon Neuroscience Research Network, Dhaka, Bangladesh.
Chanchal KumarDepartment of Medical Microbiology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.
Giridhari PalVallabhbhai Patel Chest Institute, University of Delhi, New Delhi, 110007 Delhi, India.
SahilDepartment of Computer Science, Panjab University, Chandigarh, India.
Kamal ShrivastavaDepartment of Medical Microbiology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.
Gokhan ZenginSelcuk University, Selçuklu, Konya, Turkey.
Sandeep AroraChitkara College of Pharmacy, Chitkara University, 140401, Punjab, India.
Chitkara University · INUniversity of Delhi · INPanjab University · INSelçuk University · TRSoutheast University · BDUniversity of Oradea · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The novel corona virus disease has shaken the entire world with its deadly effects and rapid transmission rates, posing a significant challenge to the healthcare authorities to develop suitable therapeutic solution to save lives on earth. The review aims to grab the attention of the researchers all over the globe, towards the role of ACE2 in COVID-19 disease. ACE2 serves as a molecular target for the SARS-CoV-2, to enter the target cell, by interacting with the viral glycoprotein spikes. However, the complexity began when numerous studies identified the protective response of ACE2 in abbreviating the harmful effects of vasoconstrictor, anti-inflammatory peptide, angiotensin 2, by mediating its conversion to angiotensin-(1-7), which exercised antagonistic actions to angiotensin 2. Furthermore, certain investigations revealed greater resistance among children as compared to the geriatrics, towards COVID-19 infection, despite the elevated expression of ACE2 in pediatric population. Based upon such evidences, the review demonstrated possible therapeutic interventions, targeting both the protective and deleterious effects of ACE2 in COVID-19 disease, primarily inhibiting ACE2-virus interactions or administering soluble ACE2. Thus, the authors aim to provide an opportunity for the researchers to consider RAAS system to be a significant element in development of suitable treatment regime for COVID-19 pandemic.

Indexed as

AgedAged, 80 and overAge FactorsAngiotensin-Converting Enzyme 2Anti-Inflammatory AgentsBetacoronavirusChildChild, PreschoolCoronavirusCoronavirus InfectionsCOVID-19FemaleGeriatricsHumansInfantInfant, NewbornACE2 protein, humanAngiotensin-Converting Enzyme 2Anti-Inflammatory AgentsPeptidyl-Dipeptidase AReceptors, VirusACE2Angiotensin-(1–7)Angiotensin 2Corona virusGlycoprotein spikesRAAS system

Identifiers

PMID32653522
PMCPMC7347488
OpenAlexW3042094126

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.